Novartis Reports 3 Patient Deaths. Why the Stock Is Heading for Its Best Day Since 2023. - Barron's

Novartis Reports 3 Patient Deaths. Why the Stock Is Heading for Its Best Day Since 2023. - Barron's
Business

Listen to this article

0%

Novartisreleased a mixed bag of clinical updates, pausing trials for one drug after a spate of patient deaths, while simultaneously revealing positive data for a pill that analysts view as a potentia… [+113 chars]

Leave A Comment

Comments are moderated and may take time to appear.

Comments

No comments yet. Be the first to comment!

Stay Connected